Newsletter 14/2025
/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! This week too, there are only a few articles, but they’re very interesting. To fill the space, I wrote longer summaries! But they’re worth reading—new approaches and new clinical trials are on the horizon. Stay strong and fight on! […]
IDOV-Immune A Viral Therapy Turning the Tide Against Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 for TTX-MC138: Breakthrough RNA Therapeutic Advances in Targeting Metastatic Cancers
/in Clinical Trial, Metastatic, Phase 1/by MaxUPDATE On ENV105: Safety Lead-In Completed for This Innovative Therapy
/in Clinical Trial, Metastatic, Phase 2/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- A-DREAM Trial Suggests Some Men with Metastatic Prostate Cancer May Stop Therapy Safely for a Time May 22, 2026
- Phase 2 TALENT Trial: Talazoparib as Monotherapy or With Enzalutamide in HRR-deficient mCRPC May 22, 2026
- ABBV-969 in mCRPC: Dual‑Targeting ADC Shows Robust PSA and Objective Responses in Heavily Pretreated Patients May 22, 2026
- CONVERGE-01: CONV01-α Shows Activity After Lu-PSMA in mCRPC May 22, 2026